Cometriq 100 mg Daily Dose Carton Pack
RxNorm 1363410

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1363410 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Cometriq 100 mg Daily Dose Carton Pack.

The following semantic concepts and normalized strings are associated with this clinical entity:

SY
4 {7 (cabozantinib 20 mg Oral Capsule [Cometriq]) / 7 (cabozantinib 80 mg Oral Capsule [Cometriq]) } Pack [Cometriq 100 mg Daily Dose Carton]
AUI:5041223
PSN
Cometriq 100 mg Daily Dose Carton Pack
AUI:6375237
SY
Cometriq 100 mg Daily Dose Carton Pack
AUI:5041224
SY
Cometriq 100 mg Daily Dose Carton Pack, 4 Blister Cards, 14 Capsules Each
AUI:5041222
BPCK
{28 (cabozantinib 20 mg Oral Capsule [Cometriq]) / 28 (cabozantinib 80 mg Oral Capsule [Cometriq]) } Pack [Cometriq 100 mg Daily Dose Carton]
AUI:5041221

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SYPrescribable

Synonym (SY):
4 {7 (cabozantinib 20 mg Oral Capsule [Cometriq]) / 7 (cabozantinib 80 mg Oral Capsule [Cometriq]) } Pack [Cometriq 100 mg Daily Dose Carton]
(Atom ID: 5041223)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
4 {7 (cabozantinib 20 MG Oral Capsule [Cometriq]) / 7 (cabozantinib 80 MG Oral Capsule [Cometriq]) } Pack [Cometriq 100 MG Daily Dose Carton]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1363410
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
5041223
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1363410
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

PSNPrescribable

Prescribable Name (PSN):
Cometriq 100 mg Daily Dose Carton Pack
(Atom ID: 6375237)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Cometriq 100 MG Daily Dose Carton Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1363410
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6375237
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
1363410
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

SYPrescribable

Synonym (SY):
Cometriq 100 mg Daily Dose Carton Pack
(Atom ID: 5041224)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Cometriq 100 MG Daily Dose Carton Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1363410
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
5041224
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1363410
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

SYPrescribable

Synonym (SY):
Cometriq 100 mg Daily Dose Carton Pack, 4 Blister Cards, 14 Capsules Each
(Atom ID: 5041222)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Cometriq 100 MG Daily Dose Carton Pack, 4 Blister Cards, 14 Capsules Each
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1363410
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
5041222
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1363410
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

BPCKPrescribable

Brand Name Pack (BPCK):
{28 (cabozantinib 20 mg Oral Capsule [Cometriq]) / 28 (cabozantinib 80 mg Oral Capsule [Cometriq]) } Pack [Cometriq 100 mg Daily Dose Carton]
(Atom ID: 5041221)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{28 (cabozantinib 20 MG Oral Capsule [Cometriq]) / 28 (cabozantinib 80 MG Oral Capsule [Cometriq]) } Pack [Cometriq 100 MG Daily Dose Carton]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1363410
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
5041221
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
BPCK
Brand Name Pack ({# (Ingredient Strength Dose Form) / # (Ingredient Strength Dose Form)} Pack [Brand Name])
Source Code
1363410
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

Patient Education

Cabozantinib (liver and kidney cancer)


Cabozantinib (Cabometyx) is used to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the cells of the kidneys). It is also used along with nivolumab (Opdivo) to treat advanced RCC in patients who have not yet received a treatment for RCC. Cabozantinib (Cabometyx) is also used to treat hepatocellular carcinoma (HCC; a type of liver cancer) in people who were previously treated with sorafenib (Nexafar). Cabozantinib (Cabometyx) is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Cabozantinib is also available as a capsule (Cometriq) to treat a certain type of thyroid cancer. This monograph only gives information about cabozantinib tablets (Cabometyx) for advanced RCC or HCC. If you are using this medication for thyroid cancer, read the monograph entitled cabozantinib (thyroid cancer).
[Learn More]


Cabozantinib (thyroid cancer)


Cabozantinib (Cometriq) is used to treat a certain type of thyroid cancer that is getting worse and that has spread to other parts of the body. Cabozantinib (Cometriq) is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Cabozantinib is also available as a tablet (Cabometyx) to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the cells of the kidneys) and hepatocellular carcinoma (HCC; a type of liver cancer) in certain patients who have previously been treated with another medication. This monograph only gives information about cabozantinib capsules (Cometriq) for thyroid cancer. If you are using this medication for advanced RCC or HCC, read the monograph entitled cabozantinib (liver and kidney cancer).
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.